A new discussion paper published in Supportive Care in Cancer by an international team led by researchers at Flinders University in Australia, working under the auspices of the Multinational Association of Supportive Care in Cancer (MASCC), confronts this problem head-on. The authors examine a pragmatic and increasingly influential strategy known as resource stratification, in which evidence-based clinical guidelines are adapted to the level of resources and health system capacity within a specific country or region. The approach was pioneered by the Breast Health Global Initiative, endorsed by the World Health Organization, and adopted by heavyweight bodies including the National Comprehensive Cancer Network and the American Society of Clinical Oncology. Now MASCC has developed and is piloting a standardized policy for resource-stratifying its own supportive care guidelines—and in doing so, it has run into five critical challenges that the paper dissects in detail.

The mechanics of resource stratification are conceptually elegant. The most common method, and the one MASCC has adopted, is to take a so-called parent guideline and adapt it to resource-constrained settings with input from experts. The resources required for a given intervention in a given context are identified and ranked by their relative importance and their impact on outcomes. Recommendations are then aligned to the highest achievable resource level in a setting, with hypothetical scenarios used to guide implementation. A staircase approach defines tiered resource levels—from basic to core to enhanced services—and recommends stepwise pathways for climbing from one tier to the next. Crucially, because these tiers are anchored to facility-level infrastructure and workforce availability rather than national income classification alone, the framework can also capture low-resource pockets within wealthy countries, which face challenges that are distinct from, rather than simply lesser versions of, those in low- and middle-income countries.

The first and perhaps most fundamental challenge is the evidence base itself. Resource stratification of a parent guideline typically relies on evidence generated in high-income countries, which may not adequately reflect the realities of low- and middle-income settings. Randomized controlled trials, the gold standard of clinical evidence, are largely conducted in wealthy nations and are typically designed to prioritize internal validity over external validity—the very quality that determines whether findings translate to a district hospital in a low-resource region. Compounding the problem, evidence appraisal systems that rank evidence using traditional quality hierarchies can inadvertently underrepresent cancer research from low- and middle-income countries, and high-impact journals have demonstrated editorial and review bias against submissions originating from those settings. The authors argue that while randomized trials and systematic reviews should remain the cornerstone of guideline development, a more inclusive approach to evidence synthesis is needed—one that considers observational research, qualitative studies, implementation science methods, and context-specific real-world data from local institutions, evaluated through transparent expert consensus.

Economics adds another layer of complexity. Robust cost-effectiveness analyses of supportive cancer care interventions in low- and middle-income countries are scarce, and applying results from wealthy countries to poorer ones is hazardous, because healthcare costs, financing structures, and the downstream consequences of care vary substantially between settings. Out-of-pocket expenses are often higher in low- and middle-income countries and can be financially catastrophic for patients and their families. This variation makes it difficult to calibrate the strength of recommendations based on cost alone, though partial economic evaluations, cost descriptions, and budget impact analyses from these settings may offer relevant evidence. Until more local research exists, the authors conclude, pragmatic assumptions and flexible interpretation of existing evidence are necessary to keep progress moving.

The second challenge is access. Availability of supportive care varies enormously across the globe and even within single countries, regions, and hospitals, meaning an intervention may be feasible in one setting but not another, even within the same resource category. Access itself is multidimensional, shaped by availability, affordability, acceptability, approachability, and cultural appropriateness. In many low- and middle-income countries, essential supportive care medications such as antiemetics, analgesics, and anxiolytics may not appear on national essential medicines lists, while unstable supply chains, regulatory hurdles, policy constraints, and workforce shortages hinder consistent delivery. The scale of the inequity is stark: 80 percent of the world’s population, mostly in low- and middle-income countries, consumes only 14 percent of the morphine used globally. MASCC research has also documented wide variation in the availability of optimal antiemetics for highly emetic chemotherapy protocols across Eastern European, Balkan, and Southeast Asian countries.

By explicitly weaving feasibility, availability, and affordability into guideline development, resource-stratified guidelines attempt to close the gap between what guidelines recommend and what clinicians can actually deliver. Rather than assuming universal access to optimal interventions, recommendations are tiered to reflect what is achievable, allowing evidence-based alternatives when standard options are inaccessible. Organizations such as MASCC cannot directly influence regulatory approvals, but through its global network it can document disparities, promote context-specific implementation strategies, support research on low-cost interventions, and disseminate evidence through international academic and policy channels. The underlying principle is that patients have the right to the best achievable quality of life, and that supportive care is integral to oncology practice rather than an optional add-on.

The third challenge is representation. Meaningful participation of individuals from low- and middle-income countries at every stage of guideline development, from topic selection through implementation, is essential for producing guidance that is relevant, feasible, and sustainable. Without it, panels lack the contextual knowledge to judge whether recommendations will work in diverse resource-constrained settings. Yet achieving such representation is difficult: competing clinical demands, limited internet connectivity, time zone differences, and a lack of institutional support all conspire against participation. The MASCC Antiemetic Guideline Group offers one pragmatic solution—a repository of names and contact details of interested clinicians in low- and middle-income countries, providing a mechanism for recruiting panel members with genuine lived clinical experience in resource-constrained environments. Flexible meeting formats, asynchronous collaboration, authorship and leadership recognition, and embedded capacity-building can further ease the barriers.

The fourth challenge is distinctive to supportive care: resource prioritization must be driven primarily by patient-reported outcomes. Where anticancer treatment typically prioritizes tumor control or survival, supportive care focuses on preventing and alleviating the physical, psychological, social, and practical consequences of cancer and its treatment. Outcomes such as symptom burden, function, distress, treatment adherence, caregiver burden, and patient experience are therefore central, not secondary, and must be weighed and ranked alongside cost, feasibility, and availability. The authors note that even in wealthy countries, high levels of unmet supportive care needs have persisted while anticancer therapies advanced rapidly, suggesting health systems systematically emphasize survival-focused biomedical treatment over quality of life. In resource-constrained settings, this imbalance may be even more pronounced, amplified by inadequate infrastructure, donor-driven agendas, and competing priorities.

The final challenge is perhaps the most subtle: misunderstanding of purpose. Clinicians and policymakers have expressed concern that resource-stratified guidelines could be misread as legitimizing substandard care, or as disincentivizing investment in international best-practice standards. Payers and regulatory bodies might even interpret them as justification for withholding optimal supportive care, even when such interventions are relatively low-cost and highly effective. In that scenario, the lowest resource tier risks becoming an endpoint rather than a stepping stone, perpetuating inequities in symptom control and quality of life. The authors insist that framing is everything: these guidelines are not cost-containment tools or ceilings on care, but instruments to optimize supportive care within existing constraints while defining practical pathways for system strengthening over time. Their intended purpose must be explicit—to support equitable improvement, not to legitimize inadequate care. As MASCC’s motto holds, supportive care makes excellent cancer care possible, in every resource setting on Earth.

Subject of Research: Resource stratification of supportive care clinical guidelines for cancer in low- and middle-income countries

Article Title: Navigating challenges in resource-stratification of supportive care clinical guidelines for cancer

Article References: Button, E., Agbejule, O. A., Bosnjak, S., Iihara, H., Ashbury, F. D., Anderson, B. O., Wong, H. C. Y., Lee, S. F., Affronti, M. L., Aapro, M. S., Soto-Perez-de-Celis, E., Chan, A., & Chan, R. J. (2026). Navigating challenges in resource-stratification of supportive care clinical guidelines for cancer. Supportive Care in Cancer, 34(11), Article 1099. https://doi.org/10.1007/s00520-026-11330-5

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11330-5

Keywords: supportive care, clinical guidelines, resource stratification, cancer, low- and middle-income countries, health equity, MASCC, patient-reported outcomes, guideline adaptation, global oncology, access to medicines, health policy

The statement, published in Supportive Care in Cancer by the Oncodermatology Study Group of the Multinational Association of Supportive Care in Cancer (MASCC), was led by Shirley S. W. Tse of the Hospital Authority in Hong Kong and Shely Kagan of the Odette Cancer Centre in Toronto, together with a multidisciplinary team of radiation oncologists, dermatologists, and nurses spanning North America, Europe, Asia, and Australia. Because high-quality trial evidence in this field remains limited, the authors chose the format of a clinical practice statement rather than a formal guideline: a practice-oriented document that distills expert consensus into actionable recommendations for clinicians who must make decisions today, even where the literature is incomplete.

To build the statement, the panel conducted a comprehensive review of the literature indexed in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, with the search extending up to April 23, 2026. The identified studies were then examined through structured discussions among the experts of the MASCC Oncodermatology Study Group, who synthesized their conclusions into a series of practical bullet points covering the entire clinical pathway: which patients should be considered for prophylaxis, how the skin should be prepared, which product to choose, how and how often to apply it, and how patients should be monitored from the start of treatment through to the discontinuation of the agent.

The biological rationale behind barrier-forming agents is rooted in the pathophysiology of radiation dermatitis itself. Ionizing radiation damages the rapidly dividing basal cells of the epidermis and triggers an inflammatory cascade that peaks in the weeks following exposure. Friction, moisture, and mechanical stress on already compromised skin accelerate the deterioration from faint erythema to moist desquamation, the wet, raw breakdown that clinicians most want to avoid. Barrier films and film-forming silicone gels work by creating a thin, flexible, semi-occlusive layer over the stratum corneum, reducing friction and shear forces, limiting transepidermal water loss, and shielding vulnerable skin folds and irregular contours where sweat and movement concentrate injury. Unlike thick ointments, these products are designed not to interfere with the radiation beam itself, a critical consideration that has historically made oncologists wary of applying anything to the skin during a treatment course.

The central recommendation of the statement is deliberately targeted rather than universal. The panel recommends barrier-forming topical agents for patients undergoing radiotherapy who are at considerable risk of developing high-grade radiation dermatitis, with a particular emphasis on treatment sites that have irregular anatomical contours. Head and neck cancer patients, whose skin must tolerate radiation across curved, mobile, and often moist surfaces around the jaw, neck, and behind the ears, emerge as the clearest beneficiaries. The panel notes that extension of prophylaxis to other anatomical subsites may be considered, but cautions that more robust data are required before routine use can be endorsed in those settings, a position that reflects both the promise of the technology and the honest limits of the current evidence base.

Among the available products, one stands out in the panel’s assessment. StrataXRT, a silicone-based film-forming gel dressing, currently has the most robust supporting evidence, according to the statement. That conclusion rests on a growing body of clinical research, including a single-blind randomized controlled trial published in Radiotherapy and Oncology in 2019, in which Chan and colleagues tested the gel as prophylaxis and management of radiation dermatitis in patients with head and neck cancer. Subsequent work has extended the evaluation to breast cancer, including a 2025 intrapatient noninferiority randomized clinical trial by Lee and colleagues, published in the International Journal of Radiation Oncology, Biology, Physics, which compared StrataXRT with Mepitel Film, a silicone mesh film, for preventing postmastectomy radiation dermatitis. The intrapatient design, in which different areas of the same patient’s skin receive different interventions, is particularly powerful because it controls for individual differences in radiation sensitivity, skin type, and treatment parameters.

The broader literature reviewed by the panel spans more than two decades of experimentation with skin protection during radiotherapy. Early paired-comparison trials, such as the 2004 study by Graham and colleagues in the Trans Tasman Radiation Oncology Group, tested no-sting barrier films against conventional sorbolene cream in postmastectomy patients, while later studies evaluated barrier creams, moisturizers, and topical corticosteroids such as mometasone furoate. A 2024 systematic review and network meta-analysis by Wong and colleagues in Breast Cancer Research and Treatment synthesized the comparative evidence on barrier films and dressings in breast cancer, and a 2026 meta-analysis by the same group directly compared Mepitel Film with StrataXRT in postmastectomy radiotherapy. Health economics has entered the picture as well: a 2026 Canadian cost-effectiveness analysis of Mepitel Film for breast cancer patients, published in Breast Cancer Research and Treatment, examined whether the upfront cost of prophylactic films is offset by the avoided costs of managing severe dermatitis, including unplanned clinical visits, dressings, and treatment delays.

The practical guidance embedded in the statement addresses questions that clinicians confront daily but that trial reports rarely answer. When should application begin, and how long should it continue? How should the skin be cleansed and prepared so the film adheres properly? What technique ensures an even layer without pooling in skin folds? How should clinicians reconcile the application schedule with radiotherapy sessions, and what signs should trigger reassessment or discontinuation? By structuring its recommendations around patient selection, skin preparation, product choice, application schedule and technique, and ongoing monitoring, the panel has effectively created a checklist that radiation oncology departments can adapt to their own workflows, from high-volume breast cancer services to complex head and neck programs.

The significance of the statement extends beyond its specific recommendations. Radiation dermatitis has long been treated as an inevitable side effect, managed reactively after redness appears rather than prevented proactively. The 2023 MASCC Delphi consensus recommendations published in The Lancet Oncology marked a first step toward standardized prevention and management of the condition; the new practice statement builds on that foundation by drilling down into one specific class of preventive agents and codifying how they should be used. The oncodermatology discipline itself, sitting at the intersection of cancer medicine and dermatology, has grown rapidly as survival rates improve and the long-term quality of life of cancer patients becomes a central measure of treatment success.

For patients, the message is that skin protection during radiotherapy is no longer a matter of folklore and improvised moisturizing, but an evolving clinical science with specific tools, defined protocols, and an evidence hierarchy. For clinicians, the statement offers a defensible consensus position in an area where definitive trial data remain sparse: reserve barrier-forming topical agents for those at considerable risk of high-grade dermatitis, prioritize sites with irregular contours such as the head and neck, and lean on StrataXRT where the evidence is strongest, while recognizing that broader routine use awaits stronger data. As radiotherapy techniques grow more precise and hypofractionated schedules become standard, the interplay between beam physics and skin biology will continue to evolve, and statements like this one provide the framework through which new evidence can be rapidly translated into everyday cancer care.

Subject of Research: Prevention of acute radiation dermatitis with barrier-forming topical agents during radiotherapy

Article Title: MASCC oncodermatology clinical practice statement: prevention of acute radiation dermatitis using barrier-forming topical agents

Article References: Tse, S. S. W., Kagan, S., Zhang, B., Yang, C., Verma, S., Wong, H. C. Y., Lee, S. F., Wolf, J. R., van den Hurk, C., Chan, R. J., Herst, P. M., Hijal, T., Bolivar, C. H. A., Chow, E., Bonomo, P., Marta, G. N., & on behalf of the Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group (2026). MASCC oncodermatology clinical practice statement: prevention of acute radiation dermatitis using barrier-forming topical agents. Supportive Care in Cancer, 34(10), Article 1057. https://doi.org/10.1007/s00520-026-11244-2

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11244-2

Keywords: acute radiation dermatitis, radiotherapy, barrier-forming topical agents, StrataXRT, oncodermatology, MASCC, clinical practice statement, supportive care in cancer, skin toxicity, head and neck cancer, breast cancer, silicone film-forming gel